Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
2022 · Annals of Oncology · 168 citations
https://doi.org/10.1016/j.annonc.2022.10.006